Literature DB >> 6422299

Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome.

H W Murray, B Y Rubin, H Masur, R B Roberts.   

Abstract

To examine the cellular immune defect that predisposes patients with the acquired immunodeficiency syndrome (AIDS) to opportunistic infections, we tested T lymphocytes from 16 patients for the capacity to secrete macrophage-activating products (lymphokines) including gamma interferon. Mononuclear cells from 10 of 11 patients did not generate an effective lymphokine in response to mitogen, and 11 of 16 produced subnormal levels of gamma interferon (less than 300 U per milliliter). In addition, upon stimulation with specific microbial antigen, cells from none of 14 patients generated active lymphokines, and cells from 13 to 14 completely failed to secrete gamma interferon. However, the antimicrobial function of monocytes from the patients was intact, and once stimulated with normal lymphokines or gamma interferon alone, macrophages derived from patients' monocytes responded with enhanced and effective intracellular antimicrobial activity. These results suggest that impaired lymphokine production may predispose patients with AIDS to opportunistic infections, and they provide a rationale for using gamma interferon as immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6422299     DOI: 10.1056/NEJM198404053101404

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  115 in total

1.  Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection.

Authors:  V Michailowsky; N M Silva; C D Rocha; L Q Vieira; J Lannes-Vieira; R T Gazzinelli
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Protective immunity against Toxoplasma gondii in mice induced by a chimeric protein rSAG1/2.

Authors:  Chung-Dar Yang; Gan-Nan Chang; David Chao
Journal:  Parasitol Res       Date:  2003-11-06       Impact factor: 2.289

Review 3.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 4.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  The role of mutation accumulation in HIV progression.

Authors:  Alison P Galvani
Journal:  Proc Biol Sci       Date:  2005-09-07       Impact factor: 5.349

6.  In vivo activation of peripheral blood polymorphonuclear neutrophils by gamma interferon results in enhanced fungal killing.

Authors:  C J Morrison; E Brummer; D A Stevens
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

7.  Effect of IFN-gamma on the proliferation of Toxoplasma gondii in monocytes and monocyte-derived macrophages from AIDS patients.

Authors:  F G Delemarre; A Stevenhagen; F P Kroon; M Y van Eer; P L Meenhorst; R van Furth
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

8.  Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms.

Authors:  K Brand; N Mackman; L K Curtiss
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Induction of interleukin-12 (IL-12) by recombinant glycoprotein gp120 of human immunodeficiency virus type 1 in human monocytes/macrophages: requirement of gamma interferon for IL-12 secretion.

Authors:  L Fantuzzi; S Gessani; P Borghi; B Varano; L Conti; P Puddu; F Belardelli
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Immunological responses of Gambians in relation to clinical stage of HIV-2 disease.

Authors:  H Whittle; A Egboga; J Todd; G Morgan; M Rolfe; S Sabally; A Wilkins; T Corrah
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.